November 2020

The Case For “Smidcaps”

Small and midcap stocks – or “smidcaps” – have had a strong November, and the author of today’s article asserts that this strong performance will continue: “This group has been beaten and battered for so long that many people simply doubt the move. But this is a big mistake. I don’t know about the next few days ahead, but smidcaps… 

The New “Billion Dollar Portfolio”

What’s attractive about stocks with a market value around $1 billion? The author of today’s article explains that “At that size, a stock is small enough so that it hasn’t yet been “discovered” by a lot of Wall Street firms, but big enough to have some heft and staying power.” Each year he selects ten stocks hovering around the billion-dollar… 

Mergers And Acquisitions Will Drive Biotech Post-Vaccine – And This ETF Could Benefit

“Once a tried-and-true [COVID-19] vaccine is developed and subsequently incorporated as standard fare in medical practice, one driver of biotech will be mergers and acquisitions,” advises the author of today’s article. He proceeds to highlight an ETF that could benefit from this particular driving force – a fund that has generated a 30% return this year. For more, CLICK HERE.

Short Opportunities For A Shortened Trading Week

Thanksgiving means it’s a shortened trading week – and today’s article features two biotech stocks to consider shorting this shortened week based on technical analysis and quantitative ratings. For these two biotech stocks that “look bearish and may present interesting investing opportunities on the short side,” CLICK HERE.

How These 3 Medical Device Stocks Beat Biotech

“When it comes to consistent profitability, long-term growth, large competitive moats, and innovation, medical device companies can provide better returns in the long run” compared to biotech stocks, advises the author of today’s article. He proceeds to highlight three medical device stocks which, while not having generated the massive returns some biotech stocks have this year, have handily beaten the… 

Important News Drops Make These 3 Biotech Stocks To Watch In The Coming Weeks

The three biotech stocks highlighted in today’s article are ones to watch carefully in the coming weeks, advises the author, as important news drops are expected – and in the case of two of the stocks, those news drops are related to the companies’ COVID-19 vaccine candidates. For more on these three biotech stocks to watch throughout the remainder of… 

These 3 Companies Could Be Buyout Targets For This Growth-Strapped Biotech

If the biotech titan that’s the focus of today’s article is going to improve its growth prospects, it may have to go acquisition shopping in the next few months – and one of the three companies that the author highlights could be its target, as he notes that all three are acquisitions that “the biotech could easily afford and that… 

Higher Highs Ahead For This Hot Biotech?

The clinical-stage biotech highlighted in today’s article, dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders, has been one of the hottest biotech stocks this year. And after a run-up that has generated triple-digit returns, there are a number of factors that could help propel it to even higher highs from here. For more on this… 

3 Stocks To Watch In The Volatility-Haunted Biotech Space

When it comes to finding the best biotech stocks to buy, the author of today’s article acknowledges that it “can be tricky given that volatility often haunts the space.” Nonetheless, he proceeds to highlight three biotech stocks to watch – two of which are working on COVID-19 vaccines while the third may be worth a look even though the company… 

What Makes This Biotech An Attractive Investment? A Promising Lead Candidate, Broad Pipeline — And More

In making the case for why the biotech featured in today’s article, which is focused on the development of novel antibody-drug conjugate therapeutics for the treatment of cancer, is an attractive investment, the analyst cited points to three primary factors: “the favorable outlook for [its lead candidate], the long-term potential of the biotech’s pipeline and the continuing validation, by partners,…